Biocryst Pharmaceuticals Inc (BCRX): who owns it and who trades it
As of Nov 16, 2026, BCRX insiders reported 9 open-market sales worth $4.1M and no purchases in the last 12 months, with 85% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alane P Barnes (Chief Legal Officer), with $3.5M. 7 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Biocryst Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Insiders and famous investors mostly sold. Funds and Congress mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BCRX
318 funds and institutions reported BCRX shares worth $2.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 9.4%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 23.89M | 9.40% | $239M | +5% |
| Ra Capital Management, L.P. | 15.83M | 6.23% | $158M | No change |
| State Street Corp | 15.19M | 5.98% | $152M | +24% |
| Deerfield Management Company, L.P. | 15.10M | 5.94% | $151M | +0% |
| Vanguard Capital Management LLC | 11.36M | 4.47% | $114M | +2% |
| Vanguard Portfolio Management LLC | 11.14M | 4.38% | $111M | -1% |
| TCG Crossover Management, LLC | 11.02M | 4.34% | $110M | No change |
| Perceptive Advisors LLC | 10.31M | 4.06% | $103M | +39% |
| Jupiter Topco LLC | 9.54M | 3.75% | $95.3M | – |
| Vestal Point Capital, LP | 8.30M | 3.27% | $83M | +18% |
| Two Sigma Investments, LP | 6.78M | 2.67% | $67.8M | +6% |
| Geode Capital Management, LLC | 6.25M | 2.46% | $62.5M | +8% |
| Aberdeen Group plc | 5.31M | 2.09% | $53.1M | +5% |
| UBS Group AG | 5.08M | 2.00% | $50.8M | +3% |
| Bank of America Corp | 4.80M | 1.89% | $48M | -6% |
| Goldman Sachs Group Inc | 4.48M | 1.76% | $44.8M | +91% |
| Frazier Life Sciences Management, L.P. | 4.01M | 1.58% | $40.1M | No change |
| Nuveen, LLC | 4.01M | 1.58% | $40.1M | +5% |
| Nantahala Capital Management, LLC | 3.80M | 1.50% | $38M | +91% |
| Millennium Management LLC | 3.39M | 1.34% | $33.9M | +1708% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, BCRX insiders reported $0 of open-market purchases and $4.1M of sales. 85% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | Amy E McKee | Director | Sale | 11,180 | $8.97 | $100K | Form 4 |
| May 13, 2026 | Alane P Barnes | Chief Legal Officer | Sale plan | 62,500 | $9.54 | $596K | Form 4 |
| Mar 20, 2026 | Theresa Heggie | Director | Sale | 49,933 | $10.11 | $505K | Form 4 |
| Mar 16, 2026 | Alane P Barnes | Chief Legal Officer | Sale plan | 150,000 | $9.15 | $1.4M | Form 4 |
| Dec 22, 2025 | Alane P Barnes | Chief Legal Officer | Sale plan | 21,773 | $7.65 | $167K | Form 4 |
| Dec 15, 2025 | Alane P Barnes | Chief Legal Officer | Sale plan | 21,210 | $7.65 | $162K | Form 4 |
| Dec 3, 2025 | Alane P Barnes | Chief Legal Officer | Sale plan | 19,770 | $7.65 | $151K | Form 4 |
| Dec 2, 2025 | Alane P Barnes | Chief Legal Officer | Sale plan | 50,906 | $7.21 | $367K | Form 4 |
| Dec 1, 2025 | Alane P Barnes | Chief Legal Officer | Sale plan | 91,004 | $7.10 | $646K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Alane P Barnes | Chief Legal Officer | – | $3.5M | May 13, 2026 |
| Theresa Heggie | Director | – | $505K | Mar 20, 2026 |
| Amy E McKee | Director | – | $100K | May 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BCRX short interest
High short interest. 10.7% of BCRX shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went down 23%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 27.64M BCRX shares were sold short, 10.7% of the shares outstanding, up 3.9% from the report before. At the average daily volume of 5.43M shares, buying them all back would take about 5.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 27.64M | 10.74% | +4% | 5.43M | 5.1 |
| Oct 15, 2026 | 26.60M | 10.41% | -3% | 4.58M | 5.8 |
| Sep 30, 2026 | 27.49M | 10.76% | -21% | 5.96M | 4.6 |
| Sep 15, 2026 | 34.87M | 13.65% | +2% | 4.78M | 7.3 |
| Aug 31, 2026 | 34.05M | 13.33% | +3% | 2.36M | 14.4 |
| Aug 14, 2026 | 32.94M | 12.89% | +0% | 4.13M | 8.0 |
| Jul 31, 2026 | 32.80M | 12.84% | +5% | 2.64M | 12.4 |
| Jul 15, 2026 | 31.21M | 12.28% | -36% | 5.25M | 6.0 |
| Jun 30, 2026 | 48.69M | 19.16% | +20% | 8.12M | 6.0 |
| Jun 15, 2026 | 40.64M | 15.99% | +11% | 3.57M | 11.4 |
| May 29, 2026 | 36.65M | 14.42% | +2% | 3.92M | 9.4 |
| May 15, 2026 | 36.11M | 14.21% | -4% | 5.93M | 6.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded BCRX
Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 0 sales of BCRX. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Jul 10, 2026, reported Sep 4, 2026.
Purchases 2Sales 0
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Jul 10, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Sep 4, 2026 | Report |
| Nov 13, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Dec 15, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Biocryst Pharmaceuticals company events
Biocryst Pharmaceuticals filed 15 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, job cuts). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Aug 4, 2026Job cutsAmended an earlier report. Announced job cuts or other exit costs. Filing
- Jun 29, 2026Job cutsAnnounced job cuts or other exit costs. Filing
- Jun 12, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of BioCryst Pharmaceuticals, Inc., a Delaware corporation, the Company’s stockholders approved, by the affirmative vote of a majority of the shares of the Company’s common stock represented in person or by proxy at the Annual Meeting and voting on the… Filing
- May 6, 2026ResultsReleased financial results. Filing
- May 4, 2026AnnouncementShared information with investors. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 23, 2026LeadershipAmended an earlier report. BioCryst Pharmaceuticals, Inc., a Delaware corporation completed the transactions contemplated by the Agreement and Plan of Merger, dated as of October 14, 2025, by and among BioCryst, Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst and Astria Therapeutics… Filing
- Jan 23, 2026DealOn the Closing Date, BioCryst completed the transactions contemplated by the Agreement and Plan of Merger, dated as of October 14, 2025, by and among BioCryst, Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst, and Astria Therapeutics, Inc., a Delaware… Filing
- Jan 12, 2026AnnouncementAs announced in the Press Release: · Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2025 was $151 million (+22 percent year-over-year; +36% year-over-year on a comparable basis, excluding European ORLADEYO revenue for the fourth quarter of 2024). · Preliminary, unaudited… Filing
- Jan 9, 2026AnnouncementShared information with investors. Filing
- Dec 12, 2025AnnouncementBioCryst Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved the Company’s new drug application for the use of an oral pellet formulation of once-daily ORLADEYO ® (berotralstat) for prophylactic therapy in pediatric patients with… Filing
- Dec 11, 2025LeadershipNancy J. Hutson, Ph.D. notified BioCryst Pharmaceuticals, Inc. of her intention to retire from the Board of Directors of the Company, effective as of the earlier of (i) the closing date of the previously announced proposed acquisition of Astria Therapeutics, Inc. and (ii) the date of the Company’s… Filing
- Dec 3, 2025AnnouncementBioCryst Pharmaceuticals, Inc. issued a press release announcing early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to its previously announced proposed acquisition of Astria Therapeutics, Inc. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Biocryst Pharmaceuticals financials
Famous investors that hold BCRX
7 of the 50 well-known investors we track reported holding BCRX in their latest 13F filing. The largest position is Ken Fisher's, worth $20.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 2.45M | $20.4M | 0.0% | -6% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.07M | $17.2M | 0.0% | -18% |
| Israel Englander · Millennium Management | Q3 2026 | 1.17M | $9.8M | 0.0% | -65% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 854,235 | $7.1M | 0.0% | +74% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 750,364 | $6.3M | 0.0% | -57% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 426,306 | $3.6M | 0.0% | +63% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 120,460 | $1M | 0.0% | -38% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named BCRX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 0.0% |
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 0.0% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.8% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.8% |
Questions about Biocryst Pharmaceuticals Inc (BCRX) stock
Who owns the most BCRX stock?
The largest reported owner of Biocryst Pharmaceuticals Inc (BCRX) is BlackRock, Inc., with 9.4% of the company. In total, 318 funds and institutions reported holding BCRX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are BCRX insiders buying or selling?
In the last 12 months, BCRX insiders reported no open-market purchases and 9 sales worth $4.1M. The latest trade was on May 18, 2026. See every trade.
What is the short interest in BCRX?
As of Oct 30, 2026, 27.64M BCRX shares were sold short, 10.7% of the shares outstanding, up 3.9% from the report before. At the average daily volume of 5.43M shares, buying them all back would take about 5.1 trading days (days to cover). See the history.
Have members of Congress traded BCRX?
Yes. 1 member of Congress reported 2 purchases and 0 sales of BCRX since Nov 17, 2024. The latest was reported on Sep 4, 2026. See the trades.
Which famous investors hold BCRX?
7 of the 50 well-known investors we track reported BCRX in their latest 13F filing, including Ken Fisher, Jim Simons, Israel Englander. The largest position is worth $20.4M. See all holders.
Executive pay
Biocryst Pharmaceuticals's chief executive was paid a total of $13M for the year ended Dec 31, 2025, up 56% from $8.3M the year before. In the last 12 months, Biocryst Pharmaceuticals's executives and directors bought no stock on the open market and sold $4.1M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.